Novel Antibody-Drug Conjugate Eliminates Residual Cancer Cells in Majority of Patients with B-Cell ALL
Key Insights
A Phase 2 study found that inotuzumab ozogamicin achieved measurable residual disease (MRD) negativity in 70% of 37 patients with B-cell acute lymphoblastic leukemia (search).
Relapse-free survival reached 40 months and median overall survival was 61 months, with the strongest outcomes seen in patients treated earlier.
The antibody-drug conjugate was well tolerated with manageable side effects and may help patients become eligible for stem cell transplant or CAR T cell therapy.
Seventy percent of patients with B-cell acute lymphoblastic leukemia (search) (ALL) achieved eradication of measurable residual disease (MRD) following treatment with the antibody-drug conjugate (ADC) inotuzumab ozogamicin, according to results from a Phase 2 study led by researchers at The University of Texas MD Anderson Cancer Center. The findings, published in Blood Cancer Journal, demonstrate that the targeted therapy can eliminate residual cancer cells even in patients who have already achieved remission, a critical step linked to improved long-term survival.
"Our results show that inotuzumab is highly effective at clearing residual disease in patients already in remission, with durable responses and encouraging survival," said principal investigator Elias Jabbour, M.D., professor of Leukemia at MD Anderson. "This approach has the potential to deepen remissions and change how we manage patients at high risk of relapse."
Study Design and Key Findings
The Phase 2 trial enrolled 37 patients with B-cell ALL and evaluated the ability of inotuzumab ozogamicin — a CD22 (search)-targeted ADC developed by Pfizer — to eliminate MRD. Among the cohort, 70% achieved MRD negativity, with strong responses observed in both Philadelphia chromosome-positive and Philadelphia chromosome-negative disease subtypes.
Patients who received treatment earlier in their disease course experienced the most favorable outcomes. Across the study population, relapse-free survival was 40 months, and median overall survival reached 61 months. The treatment was well tolerated, and side effects were manageable, according to the investigators.
Clinical Implications for B-Cell ALL
Clearing MRD is a well-established predictor of relapse risk in leukemia. When MRD becomes undetectable, patients generally have an increased chance of staying in remission. The study findings suggest that inotuzumab ozogamicin may offer patients a strong chance of clearing remaining disease, even after prior treatment with other therapies.
Beyond deepening remissions, the ADC treatment can potentially help patients reach a state where they become eligible for stem cell transplant or chimeric antigen receptor (CAR) T cell therapy in a safer, lower-disease state. This bridging potential represents an important clinical application for patients at high risk of relapse.
These findings highlight inotuzumab ozogamicin as a promising strategy to deepen remissions and potentially improve long-term outcomes by eradicating residual leukemia in patients with B-cell ALL.